Cipla is working to ensure consistent drug supplies, even as freight and fuel costs, for example, increase due to a prolonged war in West Asia, a top official with the drugmaker said, after it announced its financial performance for the fourth quarter and year ended March 31, 2026. The company’s net profit at ₹555 crore for the quarter under review was down 55 per cent from ₹1,222 crore in the same period last year. The company’s total income from operations stood at ₹6,541 crore for the period under review, down 2.8 per cent from ₹6,730 crore in the same period, last year.